权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

T-Cell Receptor Discovery for Engineered T-cell Therapy for Human Cancers

用于人类癌症工程 T 细胞疗法的 T 细胞受体发现

基本信息

批准号：
10317346
负责人：
STEVEN K. LIBUTTI
金额：
$ 150.85万
依托单位：
RBHS -CANCER INSTITUTE OF NEW JERSEY
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-03-01 至 2024-02-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10317346
关键词：
Address Advanced Malignant Neoplasm Basic Science Biometry Cancer Burden Cancer Center Cancer Control Cancer Institute of New Jersey Cancer Patient Cancer Survivor Catchment Area Cell Separation Cessation of life Clinical Research Clinical Trials Collaborations Comprehensive Cancer Center Education Family member Flow Cytometry Genomic Instability Genomics Growth Health Sciences Health system Histopathology Human Immunologic Monitoring Incidence Individual Infrastructure Institutes Institution Malignant Neoplasms Mission Names National Cancer Institute New Jersey Oncology Pathogenesis Patients Peer Review Pharmacy facility Population Population Heterogeneity Population Research Population Sciences Positioning Attribute Precision therapeutics Prevention Process Public Health Publications Publishing Quality of life Research Research Activity Research Personnel Resource Sharing Resources Risk SEER Program Science Services Statutes and Laws Strategic Planning Structure T cell therapy T-Cell Receptor Talents Therapeutic Intervention Training and Education Translating Translational Research Translations Universities Vision anticancer research authority biobank biomedical informatics cancer care cancer genetics cancer pharmacology cancer prevention cancer risk care delivery clinical care clinical investigation engineered T cells genome editing innovation inter-institutional interdisciplinary collaboration member metabolomics mortality multidisciplinary neoplasm registry next generation oncology service programs public health relevance screening small molecule tumor metabolism

项目摘要

RESEARCH PLAN – RUTGERS CANCER INSTITUTE OF NEW JERSEY OVERALL PROJECT SUMMARY/ABSTRACT The Rutgers Cancer Institute of New Jersey (CINJ) is a matrix/consortium (with Princeton University) and New Jersey’s only NCI-designated Comprehensive Cancer Center, serving a diverse population of 8.9 million people. CINJ focused the strengths and resources of the major research institutions in NJ on addressing the cancer burden in its catchment area (NJ). The rapid trajectory of CINJ’s growth validated the initial vision that one of the Nation’s largest public universities of the health sciences would rapidly bring forth an NCI-designated Cancer Center. CINJ has 227 members (206 Rutgers, 19 Princeton, and 2 collaborating). The State Cancer Registry and Surveillance, Epidemiology, and End Results (SEER) Program was moved to CINJ in 2011, and as a result of state legislation in 2013, CINJ became an independent institute of Rutgers University, optimizing CINJ’s potential for growth, transdisciplinary collaboration, and impact across the catchment area. In FY2018, CINJ received over $68 million in support from Rutgers and Princeton, the State, the Health System, and philanthropy. Direct peer-reviewed support increased ~16%. Members published 3,664 cancer focused publications since 2011 (20% inter- and 24% intra-programmatic, 55% inter-institutional). In January 2017, Steven K. Libutti was appointed Director of CINJ and Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences (RBHS). In a strategic partnership with the RWJBarnabas Health System, Libutti was named Senior Vice President for Oncology Services. CINJ is now positioned to coordinate both cancer research and care throughout its catchment area. An iterative strategic planning process resulted in reorganization of research Programs to increase collaborations, cancer focus, translation, and investigator-initiated clinical trials. These five Programs are: 1) Cancer Metabolism and Growth (CMG), 2) Genomic Instability and Cancer Genetics (GICG), 3) Cancer Pharmacology (CP), 4) Clinical Investigations and Precision Therapeutics (CIPT), and 5) Cancer Prevention and Control (CPC). These Programs are supported by eight shared resources (Biomedical Informatics, Biometrics, Biorepository and Histopathology Services, Comprehensive Genomics, Flow Cytometry/Cell Sorting, Genome Editing, Metabolomics, and Research Pharmacy), with two developing shared resources (Immune Monitoring, Small Molecule Screening). The Statewide authority of CINJ derives from its status as the only NCI-designated Cancer Center; extensive and direct support by the State of New Jersey to serve as the State’s oncology resource; opportunities to conduct translational and population research within the most diverse and densely populated State in the nation; and the synergistic opportunities for collaboration across outstanding research institutions. This supports CINJ’s mission to reduce the burden of cancer in its catchment by advancing cancer research, prevention, screening and education.

研究计划——新泽西州罗格斯癌症研究所总体项目概要/摘要新泽西罗格斯癌症研究所 (CINJ) 是一个矩阵/联盟（与普林斯顿大学）和新泽西岛唯一的 NCI 指定综合癌症中心，为 890 万人提供服务。 CINJ 集中新泽西州主要研究机构的优势和资源来解决癌症问题其流域（新泽西州）的负担。 CINJ 的快速发展轨迹验证了其中一位成员的最初愿景：全国最大的公立健康科学大学将迅速推出 NCI 指定的癌症研究中心中心。 CINJ 拥有 227 名成员（206 名罗格斯大学、19 名普林斯顿大学和 2 名合作成员）。国家癌症登记处监测、流行病学和最终结果 (SEER) 计划于 2011 年移至 CINJ，结果 2013年，CINJ成为罗格斯大学的一个独立机构，优化了CINJ的职能增长潜力、跨学科合作以及整个流域的影响力。 2018财年，CINJ 获得了罗格斯大学和普林斯顿大学、州政府、卫生系统和慈善事业超过 6800 万美元的支持。直接同行评审支持增加了约 16%。自此以来，会员发表了 3,664 篇以癌症为主题的出版物 2011 年（20% 为项目间，24% 为项目内，55% 为机构间）。 2017 年 1 月，Steven K. Libutti 被任命为 CINJ 主任和罗格斯大学生物医学与健康癌症项目副校长科学（RBHS）。在与 RWJBarnabas 卫生系统的战略合作伙伴关系中，Libutti 被任命为高级肿瘤服务副总裁。 CINJ 现在的定位是协调癌症研究和护理整个集水区。迭代的战略规划过程导致研究重组加强合作、癌症焦点、翻译和研究者发起的临床试验的计划。这五个课程包括：1) 癌症代谢和生长 (CMG)，2) 基因组不稳定性和癌症遗传学 (GICG)， 3) 癌症药理学 (CP)，4) 临床研究和精准治疗 (CIPT)，以及 5) 癌症预防和控制（CPC）。这些计划由八个共享资源（生物医学信息学、生物识别、生物样本库和组织病理学服务、综合基因组学、Flow 细胞计数/细胞分选、基因组编辑、代谢组学和研究药学），其中两个开发共享资源（免疫监测、小分子筛选）。 CINJ 在全州范围内的权威源自其作为唯一 NCI 指定的癌症中心；新泽西州的广泛和直接支持作为国家的肿瘤学资源；在该领域内进行转化和人口研究的机会全国最多元化、人口最稠密的州；以及跨领域合作的协同机会优秀的研究机构。这支持了 CINJ 减轻其辖区癌症负担的使命通过推进癌症研究、预防、筛查和教育。